Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.23 (
beta-galactosidase
)
14,648
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The properties and bile salt specificities of galactosylceramide and lactosylceramide
beta-galactosidase
activities (GC and LC-beta-galactosidases) of human leucocytes and fibroblasts were compared. A number of differences were observed. Under the standard assay conditions the former activity was more sensitive to Zn2+ and Triton-X100.
Glycocholate
and cholate were more active stimulators of the GC-
beta-galactosidase
than the more frequently used taurocholate which was the most effective stimulator of LC-
beta-galactosidase
activity. It is postulated that some of the apparent differences in the properties of GC- and LC-
beta-galactosidase
activities may be attributed to the different micellar properties of the lipid substrates. Experiments with fibroblasts from patients with Krabbe's disease confirmed an almost total absence of GC-
beta-galactosidase
whichever bile acid was employed. Residual LC-
beta-galactosidase
activity detected in these cells was much higher ranging from 13% of the lowest measured value when measured with taurocholate to approximately normal values with glycocholate. Fibroblasts obtained from patients with GM1-gangliosidosis displayed close to normal GC and LC-
beta-galactosidase
activity under our experimental conditions. The data suggest that diagnoses of Krabbe's disease should be performed with galactosylceramide rather than lactosylceramide as substrate.
...
PMID:A comparison of the properties and bile salt specificities of galactosylceramide and lactosyl ceramide beta-galactosidase activities in human leucocytes and fibroblasts. 676 28